Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 10 of 10 publications.

Walters MC, Tisdale JF, Mapara MY, Krishnamurti L, Kwiatkowski JL, Aygun B, Kasow KA, Rifkin-Zenenberg S, Jaroscak J, Garbinsky D, Chirila C, Gallagher ME, Zhang X, Ho PR, Thompson AA, Kanter J. Sustained improvements in patient-reported quality of life up to 24 months post-treatment with LentiGlobin for sickle cell disease (bb1111) gene therapy. Presented at the 2021 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; December 11, 2021. Atlanta, Georgia. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):7. doi: 10.1182/blood-2021-146905

Spira AI, Chen L, Zhou X, Gnanasakthy A, Wang L, Ungar D, Curiel R, Radford JA, Kahl BS. Symptoms, health-related quality of life, and tolerability of loncastuximab tesirine in patients with relapsed or refractory diffuse large b cell lymphoma. Blood. 2020 Nov 5;136(Suppl 1):3-4. doi: 10.1182/blood-2020-139571

Casulo C, Byrtek M, Dawson K, Zhou X, Flowers C, Farber C, Hainsworth J, Cerhan J, Link B, Friedberg J. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National LymphoCare Study. Poster presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2014. San Francisco, CA. [abstract] Blood. 2014 Dec 6; 124(21):3044. doi: 10.1182/blood.V124.21.3044.3044

Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Link BK. PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: report from the National LymphoCare Study. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):4245. doi: 10.1182/blood.V122.21.4245.4245

Nabhan C, Byrtek M, Dawson KL, Zhou X, Link BK, Friedberg JW. A proposed prognostic model for overall survival in the oldest old (>80 years old) follicular lymphoma patients. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):3058. doi: 10.1182/blood.V122.21.3058.3058

Casulo C, Byrtek M, Dawson K, Zhou X, Farber CM, Flowers CR. Early relapse of follicular lymphoma after R-CHOP uniquely defines patients at high risk for death: an analysis from the National LymphoCare Study. Presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2013. New Orleans, LA. [abstract] Blood. 2013 Nov; 122(21):510. doi: 10.1182/blood.V122.21.510.510

Martin P, Link BK, Byrtek M, Dawson K, Ziemiecki RM, Friedberg J. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 8, 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):3702. doi: 10.1182/blood.V120.21.3702.3702

Zhou X, Wang J, Zhang J, Copley-Merriman K, Torigoe Y, Reyes C. Symptoms and toxicity of rituximab maintenance (R-M) versus observation (OBS) following rituximab plus chemotherapy in patients with follicular lymphoma. Poster presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):3661. doi: 10.1182/blood.V118.21.3661.3661

Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775

Nastoupil L, Sinha R, Byrtek M, Taylor M, Cerhan JR, Friedberg J, Ziemiecki RM. A comparison of the effectiveness of first-line chemoimmunotherapy regimens for follicular lymphoma (FL) used in the United States. Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Jan; 118(21):97. doi: 10.1182/blood.V118.21.97.97